Adlai Nortye to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Adlai Nortye (NASDAQ: ANL) said members of management will participate in two investor conferences: a Fireside Chat at the 8th Annual Evercore Healthcare Conference on Dec 2, 2025, 4:15–4:35 PM ET at Loews Coral Gables Hotel (Sevilla A, Track 2) and a virtual presentation plus 1-on-1 meetings at the 36th Oppenheimer Annual Healthcare Life Sciences Conference on Feb 25–26, 2026. The company is a clinical-stage biotech focused on cancer therapies.

SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, Nov. 21, 2025 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ: ANL) (the “Company” or “Adlai Nortye”), a clinical-stage biotechnology company focused on the development of innovative cancer therapies, today announced that members of its management team are scheduled to participate in the following investor conferences:

The 8^th Annual Evercore Healthcare Conference
Format: Fireside Chat
Host: Jonathan Miller
Date and Time: Tuesday, December 2, 2025; 4:15 pm - 4:35 PM EST.
Location: Sevilla A, Track 2, the Loews Coral Gables Hotel in Coral Gables, Florida.

The 36^th Oppenheimer Annual Healthcare Life Sciences Conference
Format: Virtual Presentation and 1-on-1 meetings
Date and Time: February 25-26, 2026

About Adlai Nortye

Adlai Nortye (NASDAQ: ANL) is a global clinical-stage company at the forefront of discovering and developing innovative cancer therapies. Leveraging our dual R&D presence in the U.S. and China, we are building a robust pipeline of drug candidates focused on two key areas where we believe we can make a significant difference. (1) Next-generation cancer immunotherapies: our candidates, AN8025 (a tri-functional fusion protein of αPD-L1 x CD86 variant x LAG3 variant), a T-cell and antigen-presenting cell modulator, and AN4005 (a first-in-class oral small-molecule PD-L1 inhibitor), are designed to activate cancer immunity in novel ways. (2) RAS-targeting therapies: we are tackling RAS-driven cancers with AN9025, an oral pan-RAS(ON) inhibitor, and AN4035, a CEACAM5-targeting ADC delivering a potent pan-RAS(ON) inhibitor directly to tumors.

Forward-Looking Statement

This announcement contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “potential,” “continue,” “ongoing,” “targets” and similar statements. Among other things, statements that are not historical facts, including statements about the Company’s beliefs and expectations, the business outlook and quotations from management in this announcement, as well as the Company’s strategic and operational plans, are or contain forward-looking statements.

The Company may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission (the “SEC”), in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Forward-looking statements involve inherent risks and uncertainties. Factors that could cause the Company’s actual results to differ materially from those expressed or implied in such forward-looking statements include, but are not limited to: the initiation, timing, progress and results of the Company’s preclinical studies, clinical trials and other therapeutic candidate development efforts; the Company’s ability to advance its therapeutic candidates into clinical trials or to successfully complete its preclinical studies or clinical trials; whether the clinical trial results will be predictive of real-world results; the Company’s receipt of regulatory approvals for its therapeutic candidates, and the timing of other regulatory filings and approvals; the clinical development, commercialization and market acceptance of the Company’s therapeutic candidates; the Company’s ability to establish, manage, and maintain corporate collaborations, as well as the ability of its collaborators to execute on their development and commercialization plans; the implementation of the Company’s business model and strategic plans for its business and therapeutic candidates; the scope of protection the Company is able to establish and maintain for intellectual property rights covering its therapeutic candidates and its ability to operate its business without infringing the intellectual property rights of others; estimates of the Company’s expenses, future revenues, capital requirements and its needs for and ability to access sufficient additional financing; risks related to changes in healthcare laws, rules and regulations in the PRC and United States or elsewhere. Further information regarding these and other risks is included in the Company’s filings with the SEC. All information provided in this announcement and in the attachments is as of the date of this announcement, and the Company does not undertake any obligation to update any forward-looking statement, except as required under applicable law.

Company contact:
Investor Relations
Email: ir@adlainortye.com

FAQ

When will Adlai Nortye (ANL) present at the Evercore Healthcare Conference?

Adlai Nortye will present on Dec 2, 2025 from 4:15–4:35 PM ET in Sevilla A, Track 2 at Loews Coral Gables Hotel.

What format is Adlai Nortye's presentation at the Evercore Healthcare Conference (ANL)?

The company is scheduled for a Fireside Chat format hosted by Jonathan Miller.

When is Adlai Nortye (ANL) participating in the Oppenheimer Healthcare Life Sciences Conference?

Adlai Nortye will participate virtually with a presentation and 1-on-1 meetings on Feb 25–26, 2026.

How can investors access Adlai Nortye's (ANL) virtual presentation at Oppenheimer?

The presentation format is listed as virtual; investors should check the conference platform or the company's investor relations page for access details.

Who from Adlai Nortye (ANL) will speak at the Evercore conference?

The release states members of management will participate; a specific speaker beyond the host was not specified.

What is Adlai Nortye's (ANL) business focus noted in the announcement?

The company is described as a clinical-stage biotechnology company focused on developing cancer therapies.